Home › Research › Treatments
Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia
Giovanni Zuliani, Gloria Brombo, Tommaso Romagnoli, Michele Polastri, Francesco di Paola Dario, Marco Zuin. GeroScience, 2025-12-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The efficacy of acetylcholinesterase inhibitors (AChEI) and memantine (ME) in severe dementia remains uncertain, and real world data are limited. We evaluated the progression of cognitive decline and mortality rates in a cohort of outpatients with severe dementia treated with AChEI and/or ME or not treated, from the National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS). Overall, 703 patients (mean age:78.3 ± 7.2 years; females:56.1%) with severe dementia (Mini-Mental State Examination-MMSE ≤ 10/30) were included [407 late-onset Alzheimer's disease (LOAD), 126 Lewy body dementia (LBD), 170 vascular dementia (VD)]. Patients were grouped by treatment status: untreated (AChEI - /ME - ; n.70), AChEI only (AChEI + ; n.294), ME only (ME + ; n.215), combined therapy (AChEI + /ME + ; n.124). During follow-up (mean:1.7 ± 0.3 years; range:0.2-2.9 years) the mean MMSE scores declined by - 1.7 points (Standard Deviation: -1.55 to -1.9) in AChEI - /ME - (p for trend:0.001), - 1.5 points (-1.55 to -1.9) in AChEI + (p:0.001), - 0.7 points (-0.5 to -0.9) in ME + (p:0.09), while it increased by + 0.7 points (+ 0.4 to + 1.0) in AChEI + /ME + (p:0.001). Survival rates were 8% in AChEI - /ME - , 10% in AChEI + , 28% in ME + , and 49% in AChEI + /ME + . In Cox proportional hazards analysis (age and sex adjusted), AChEI + /ME + exhibited a 39% reduction in total mortality compared with no treatment (HR:0.61; 95%CI:0.49-0.77; p < 0.001), ME + displayed a 22% reduction (HR:0.78; 95%CI:0.65-0.94; p:0.007), while AChEI + showed no association (HR:0.97; 95%CI:0.80-1.18; p:0.75). When the Cox proportional hazards models were stratified by dementia subtype, consistent significant patterns were observed in LOAD and LBD. In this real-world cohort of older adults with severe dementia, the combination therapy (ME + AchEI) seems to be associated with the best outcomes, including a stabilization of cognitive function and reduced total mortality.
What this study adds
Evidence grade: Moderate
The record lists 703 participants. In this group of patients with severe dementia, those taking both an acetylcholinesterase inhibitor and memantine had slower cognitive decline and lower mortality than those taking neither. Reported effect size: 56.1%; HR:0.61; HR:0.78.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zuliani, G., Brombo, G., Romagnoli, T., Polastri, M., Dario, F. d. P., & Zuin, M. (2025). Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia. GeroScience. https://doi.org/10.1007/s11357-025-02052-3
Vancouver
Zuliani G, Brombo G, Romagnoli T, Polastri M, Dario FdP, Zuin M. Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia. GeroScience. 2025. doi:10.1007/s11357-025-02052-3. PMID: 41396413.
BibTeX
@article{zuliani2025-41396413,
author = {Zuliani, Giovanni and Brombo, Gloria and Romagnoli, Tommaso and Polastri, Michele and Dario, Francesco di Paola and Zuin, Marco},
title = {{Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia}},
journal = {GeroScience},
year = {2025},
doi = {10.1007/s11357-025-02052-3},
pmid = {41396413},
url = {https://doi.org/10.1007/s11357-025-02052-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Overall, 703 patients (mean age:78.3 ± 7.2 years; females:56.1%) with severe dementia (Mini-Mental State Examination-MMSE ≤ 10/30) were included [407 late-onset Alzheimer's disease (LOAD), 126 Lewy body dementia (LBD), 170 vascular dementia (VD)].
- In Cox proportional hazards analysis (age and sex adjusted), AChEI + /ME + exhibited a 39% reduction in total mortality compared with no treatment (HR:0.61; 95%CI:0.49-0.77; p < 0.001), ME + displayed a 22% reduction (HR:0.78; 95%CI:0.65-0.94; p:0.007), while AChEI + showed no association (HR:0.97; 95%CI:0.80-1.18; p:0.75).
- When the Cox proportional hazards models were stratified by dementia subtype, consistent significant patterns were observed in LOAD and LBD.
- In this real-world cohort of older adults with severe dementia, the combination therapy (ME + AchEI) seems to be associated with the best outcomes, including a stabilization of cognitive function and reduced total mortality.
Why it matters
In this group of patients with severe dementia, those taking both an acetylcholinesterase inhibitor and memantine had slower cognitive decline and lower mortality than those taking neither. Memantine alone was also linked to lower mortality, but this was an observational study, so it cannot prove that these drugs caused the differences.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants703
- Effect size56.1%; HR:0.61; HR:0.78
- Evidence strengthModerate
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (GeroScience) |
| Journal's citation record | 1 / 4 | GeroScience: journal h-index 83 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 703 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Marco Zuin: h-index 31 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Ferrara: institution h-index 666 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41396413) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Related studies in Treatments from nearby years
Also tagged “glp1-agonists-and-ad-progression”
3 studies in the library carry the topic tag “glp1-agonists-and-ad-progression”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.